Analysts’ Weekly Ratings Changes for Medline (MDLN)

Several analysts have recently updated their ratings and price targets for Medline (NASDAQ: MDLN):

• 5/7/2026 – Medline was given a new $42.00 price target by Deutsche Bank Aktiengesellschaft.
• 5/7/2026 – Medline had its price target lowered by Citigroup Inc. from $60.00 to $55.00. They now have a “buy” rating on the stock.
• 5/7/2026 – Medline had its price target lowered by Sanford C. Bernstein from $56.00 to $54.00. They now have an “outperform” rating on the stock.
• 5/7/2026 – Medline had its “buy” rating reaffirmed by BTIG Research. They now have a $55.00 price target on the stock.
• 4/27/2026 – Medline was downgraded by Weiss Ratings from “hold (c)” to “hold (c-)”.
• 3/16/2026 – Medline is now covered by Weiss Ratings. They set a “hold (c-)” rating on the stock.

Medline (NASDAQ: MDLN) is a healthcare products and services company that manufactures, sources and distributes a wide range of medical supplies and equipment for healthcare providers. Its product portfolio spans clinical consumables and personal protective equipment, surgical and procedural supplies, wound care and incontinence products, diagnostic and laboratory supplies, and select durable medical equipment. Medline supports care settings that include hospitals, health systems, long-term care facilities, ambulatory clinics and home health providers.

In addition to product manufacturing and distribution, Medline provides supply?chain and logistics services designed to help healthcare customers manage inventory, reduce costs and streamline operations.